Skip to main content

Research & Innovation

Increase Text Size
Decrease Text Size
 Change Text Size 
Taking Healthcare Technologies to Market

Explore the intersection of innovation, policy and health delivery systems for commercial success.

Successfully bringing a health technology to market can be very rewarding. However, the challenges faced along the road to commercialization are the highest of any sector. Increasingly, the complexity of products, high capital burn rates, the regulatory landscape, and the complex payment processes all serve as make-or-break issues for innovators hoping to commercialize health technologies.

This one-day workshop will lay out the road map for researchers, innovators, and entrepreneurs to overcome the “big five” hurdles to bringing medical technologies to market:

  • Protecting your invention and assessing freedom-to-operate
  • Accessing the market and revenue strategies
  • Initial funding strategies
  • Regulatory approvals around the world
  • Driving clinical and retail adoption

Whether you are in the early stages of prototype development or thinking about moving forward with protection, this workshop will equip you with the knowledge to successfully navigate the entire product development and commercialization continuum.

We can help you understand how to develop your unique value proposition and move to commercial deployment by taking advantage of recent market shifts including health IT, workflow savings, vendor value chains, and big box retail in the healthcare space. You will leave the workshop with the necessary tools and knowledge to attract big capital and commercial players, helping you to reach the over $500 billion dollar North American health care market.


  • You have an initial idea – learn what you need to take that to market
  • Explore the range of clinical use cases
  • Plan for implementing compliant quality systems
  • Understand the regulatory maze
  • Explore market considerations and potential revenue models both SoC and private pay
  • Understand reimbursement and make the clinical business case
  • Recruit key opinion leaders (KOLs) and position to penetrate market
  • Learn about options to finance your venture


  • Position as an innovative health delivery system — both internally and externally
  • Empower clinicians and staff to seek out innovations to enhance patient care to:
  • Achieve greater precision and safety
  • Provide a more comfortable patient experience
  • Improve coordination and workflow
  • Promote as pre-eminent clinical & health economic assessment site selection for companies and their new technologies
  • Be on the forefront of new technologies for superior patient outcomes and cost savings
Sylvain Beaudry

Sylvain Beaudry is the President of MEDICUS Consulting Group. He is an internationally recognized health care management consultant that has held several management positions during his 12 years in government, 6 years in professional consulting, and 3 years with a leading multinational healthcare company. His rare combination of political, government, and health care experience provides Sylvain with a unique understanding on how to operate in the highly regulated health care industry. As a consultant, Sylvain has developed strategies to increase sales and market share that have generated over $1.5 Billion in additional revenues for his clients.

Sylvain has a B.A. in political Science from Carleton University and a Masters in International Management from the University of Quebec’s ÉNAP.

Debra Chanda

Debra Chanda, Managing Director, launch120 Inc., has over two decades of experience in operations, sales and marketing in the healthcare, financial and technology sectors. Her product portfolio areas of market representation include enterprise technology, spine, cardiovascular, wound care, rehabilitation robotics, and health and wellness, each achieving year-over-year above average growth rates. She has formerly held the positions of Vice-President of Sales and Marketing for Adagen Medical International Inc., National Product Marketing Manager for Medtronic, and Director of Marketing, Fountainhead Ventures, LLC.

Debra was the first Canadian Ambassador for Singularity University, and the former communications manager for the Chairman of the Standing Committee for Agriculture and Agri-food at the House of Commons. She is formerly an Adjunct Professor of Marketing at Georgia Institute of Technology and served on the Boards of the Southeastern Medical Device Association and the Southeastern Internet Society. Debra currently works with North American venture / investment groups in providing due diligence and interim operational management for portfolio companies. She holds degree from the University of Western Ontario. Debra grew up on a farm in Southwestern Ontario.

Patrick Clifford

Patrick Clifford, BA, BSW, BEd, MSW, RSW, is currently the Director of Research and Innovation at the Research Institute of the Southlake Regional Health Centre in Newmarket Ontario. Southlake is a community and regional acute care hospital serving a local community of 250,000 individuals through seven regional programs, with 3000 staff, 450 physicians, and a 350 million dollar operating budget. The Centre is also a test site for collaborative innovations.

Patrick’s responsibilities include oversight of research operations and infrastructure and advancing innovation, commercialization activities, and culture building through strategic collaborations with industry, academia, funders, and other key partners. Currently, Patrick leads the development and implementation of Southlake's Research Strategic Plan and works to advance the commercialization strategy, which includes developing and operating CreateIT Now, an incubator for health related innovation.

Patrick has years of experience in leadership with Professional Practice (standards, regulation and operationalization of regulated health professionals), and his early career focused on clinical service delivery to patient populations across the health sector, specializing in mental health and psychiatric emergencies. Patrick is a member of the Canadian Association of Research Ethics Boards and an executive member of the Network of Networks among other national, provincial, and local boards and committees.

Jeffrey Coull

Jeffrey Coull, PhD is a serial entrepreneur and neuroscientist. Currently, he is a Director at the Ontario Brain Institute, and is involved with two start-ups in therapeutics and medical diagnostics, respectively. Previously, Dr. Coull was President and CEO of Chlorion Pharma, a company he co-founded and which developed novel therapies for neurological disorders. Jeff also co-founded KineRx Neurosciences, a specialty pharmaceutical company focused on movement disorders. He was instrumental to KineRx’s 2010 acquisition of the Canadian rights to TASMAR®, a marketed COMT inhibitor for the treatment of Parkinson’s disease. Jeff began his career as a management consultant, providing strategic and operational advisory services to life sciences companies, including several Fortune 500 clients. He holds a PhD in pharmacology from McGill University, is an Adjunct Professor at the University of Toronto, and is a member of the Schulich School of Business Health Industry Management Program Advisory Board.

Dr. Wendy Cukier

Wendy Cukier, MA, MBA, PhD, DU (Hon), LLD (Hon), M.S.C. (civilian), as Vice-President of Research and Innovation at Ryerson University, leads the strategy to grow research and to promote innovation and commercialization. Under her leadership, Ryerson has expanded its multi-stakeholder collaborations and research funding has grown by 40% in the past two years alone. Previously, she was the Associate Dean of the Ted Rogers School of Management, Canada’s largest business school. She has written more than 200 papers on enabling technologies and innovation and is the coauthor of the bestseller “Innovation Nation: From Java to Jurassic Park”. Recent work has focused on social innovation processes in larger systems including the National Health Service in the UK.

Wendy has more than 30 years experience in the ICT sector with a focus on technology development and innovation processes. She worked as a consultant with IDC Canada and the Institute for the Future (Palo Alto, California).

Wendy serves on the Board of Directors of the Consortium for Aerospace Research and Innovation in Canada (CARIC), NPower, the Environics Institute, Women’s College Hospital and several hi-tech start-ups. She is a recipient of the Governor General's Meritorious Cross, one of Canada’s highest civilian honours and was named one of the University of Toronto's 100 Alumni Who Shaped the Century. She also received the Canadian Public Health Association, award of merit.

John Funkhouser is a current Partner of Integris, LLC, as a financing and merger and acquisition specialist to middle market companies. His three principal areas of expertise are consumer, technology, and medical devices/services. He is founder and former CEO of nContact Inc., leading the company in design beta testing, regulatory approval, animal & human studies, manufacturing and quality implementation, early commercialization, procedure evolution, IDE design and initiation, and the development of hospital disease management programs. John has raised over $45MM in venture financing, $10MM in private equity placements, and up to $20MM in debt placements for nContact, Inc. He is also a former Chairman and CEO of PharmaNetics, a publicly held medical device manufacturer, where he worked to develop rapid point of care diagnostic tests to monitor individual effects of anticoagulant drugs on patients.

John is also former general partner of Hillcrest Group, where he managed $45MM in holdings. John has served on over ten venture boards and is primarily called on to transform companies.

Lahav Gil

Lahav Gil is a senior industrial designer, technology entrepreneur, innovator, strategist, and business leader with 25 years of experience in opportunity assessment, technology transfer, product development, and technology commercialization, particularly in Medtech. He is an ambassador for design-led businesses and values-driven leadership, with a passion for using business as a medium to make a better world.

Lahav is the CEO and founder of the Kangaroo Group (ISO 13485), a fully integrated Product Development firm, Industrial Design studio, and Technology Innovation and Commercialization Accelerator, immersed in the Medtech startup universe. Lahav is a co-founder and investor for several technology startups — the most recent ones being CanFocus Technologies and NRGyze Technologies, where he holds a lead management and visioning role — and was one of the early investors in Ultrasonix Medical in 2001, an innovative US diagnostics company that was acquired recently by Analogic for over $80M. Lahav also consults to a number of Medtech startups like Cellaegis Devices and XOR Labs Toronto. For over 25 years Lahav has worked alongside investors, CEOs, doctors, and engineers in multi-stakeholder commercialization environments, helping to bring the right product to the right markets.

Jason Grier

Jason Grier is a founder of Santis Health and has nearly twenty years of experience in public affairs and communications and recently served as the Vice President and National Director of Health Policy at Hill & Knowlton Canada. He has worked with Ontario Hospital Association, Emergis, Merck, the Rick Hansen Institute, Service Employees International Union (Local 1), Novartis, the College of Medical Radiation Technologists of Ontario, and Canada Health Infoway. In the public sector, Jason has served as chief of staff to Ontario’s Minister of Health and senior health policy advisor working on the Ontario government’s most strategic and transformative health policy initiatives, such as LHINs, Family Health Teams, and the Wait Times Strategy. Jason also has experience on the senior management team of Wellesley Central Hospital and St. Michael’s Hospital.

Sam Ifergan

Sam Ifergan, Partner and President, iGan Partners, has over 15 years of entrepreneurial, technology and venture capital experience. As leader of the iGan Partners team, he is involved in evaluating new investment prospects, structuring transactions, helping companies raise funds, and leading the firm's other efforts with respect to portfolio companies. Sam has been extensively involved with entrepreneurial companies, often serving as CEO, particularly in the early stages of each company's development. Prior to founding iGan, he co-founded several companies including Visualsonics, Tri-Link Technologies and Brighter Minds. Prior to that he was a strategy consultant with Mercer Management Consulting (now Oliver Wyman) where he advised Fortune 500 companies on corporate strategy. Sam has also held general management roles at NCR, where he led the deployment of enterprise-grade information technology systems.

Sam holds a Bachelor of Electrical Engineering from McGill University and an MBA from the John Molson School of Business.

Olga Joloudeva, BA, MA, MBA, is a National Account Manager with Johnson & Johnson Medical Companies (JJMC). Olga’s experience includes 15 years with Johnson & Johnson in various sales and marketing roles for both pharmaceutical and medical devices. Most recently, Olga has been working with senior clinical and administrative leaders of some of the largest hospitals in Ontario to explore pathways for strategic relationships and greater value delivery. Olga has also been leading JJMC strategy around national procurement initiatives with the largest Canadian Group Purchasing Organization and several Shared Services Organizations in Ontario and Western Canada.

Robert Kaul

Robert Kaul, Founder and President of Cloud DX, is a serial entrepreneur specializing in bringing Canadian technologies to the US since 2005. Robert has considerable experience in launching start-up companies, arranging financing, recruiting and leading high-performing teams, building new business relationships, and marketing (including creative). His company Cloud DX is based in Toronto Canada and Brooklyn NY, and offers state-of-the-art Pulsewave® vital sign monitors to medical professionals, particularly in the US. CLOUD DX is a Top-10 Finalist and the sole remaining Canadian entry in the Qualcomm Tricoder XPRIZE Competition. The team proposed to build the Vitaliti™ Platform, combining Pulsewave® sensing technology, Cloud Diagnostics® software, and a new proprietary in-vitro diagnostics platform (IVDP) into a system capable of autonomously diagnosing 15 separate health conditions, ranging from sleep apnea to stroke.

Robert is also the former CEO of Cloud Diagnostics LLC, a healthcare IT distribution company he founded in 2009. The company was sold to Biosign Technologies Inc. in 2010, and Robert served as Executive VP of Biosign from 2010-2011, and CEO from 2012-2014.

Jennifer MacInnis

Jennifer MacInnis, LLM, LLB, Senior Director of Applied Research and Commercialization at the Office of the Vice-President, Research and Innovation at Ryerson University, is an accomplished intellectual property and contracts lawyer. With significant university and hospital experience in research contract drafting and negotiation, invention evaluation and licensing, and research policy development, Jennifer plays a key role in the administration of research investment in Ryerson.

In her role as Senior Director of Applied Research and Commercialization, Jennifer serves as a research liaison to the University, facilitating collaborative relationships with industrial, not for profit and government partners to undertake applied research with University faculty. Jennifer facilitates the accessing of research funding and provides commercialization advice, support and oversight. In addition to her responsibilities as Senior Director, Jennifer serves as Legal Counsel to the University on research related matters. Jennifer oversees a team of three Research Contracts Officers and ensures their efforts and contributions support both the internal and external activities of the Office of the Vice-President, Research and Innovation.

Diana H. Pliura, Ph.D, is CEO and Co-founder of MyndTec Inc. Prior to her full-time role at MyndTec, she was President of ALBRY Inc, providing strategic advisory and management services to emerging life sciences companies, investors, technology transfer offices, and established companies undergoing transition. Previously, she has served as Entrepreneur-in-Residence with, the Health Technology Exchange; Executive Vice President at YM BioSciences; founding CEO of DELEX Therapeutics Inc; Company Creator to the Eastern Technology Seed Investment Fund; Scientific Advisor to MDS Capital Corp; Vice President of Research at Hemosol Inc. and Head of the Division of General Biochemistry at Syntex (Canada) Research. She received her Ph.D (Chemistry) from the University of Toronto and completed post-doctoral studies at Harvard University.

Geetha Rao

Dr. Geetha Rao, Ph.D is CEO of Technology Frontiers Collaborative. Dr. Rao has over 25 years of experience in high-risk technologies with a focus on emerging business challenges and operational excellence. She is an internationally recognized expert in medical device risk management and has served on several international policy making bodies and as an invited expert to regulatory agencies. Between 2009 and 2014, she produced MedTech Frontiers, an educational forum in the San Francisco Bay Area that explored the intersection of leading-edge science and technology with medicine.

She has served on the faculty of FutureMed at Singularity University, Stanford University’s Biodesign Innovation Program, and on University of Chicago’s Innovation Network for the Physical Sciences Division. She was a contributor on the 2013 World Economic Forum research project on Sustainable Health Systems, a TEDMED scholar, and has addressed numerous industry forums and the press. Geetha holds a doctorate from MIT and a Master’s from Stanford University’s Graduate School of Business.

Bob Saunders currently serves as General Partner of OCA Ventures, Chicago, IL. He is also co-founder and Chairman of Xlerate Health, an enterprise-focused firm that helps early-stage healthcare companies build out their commercialization strategy, which includes their intersection with Payers, Providers (hospitals, ACOs, nursing homes, home health and group practices), and customers (employers and/or consumers). Previously, Bob served as Senior Managing Director of Chrysalis Ventures from 1997-2009, managing Chrysalis’ technology investment practice.

As a super angel investor, Bob has been an important contributing force behind several early-stage ventures including: Stonestreet One, Boardroom Events, IMC Licensing, Backupify, US WorldMeds, Aptamera, Sanbolic, Bioscale, Vivorte, Carrot Medical, NxPharmagen, SeIkowave Imaging, and Summit BioScience, among others. Bob was a founding board member of MetaCyte Business Lab, a life science incubator at the University of Louisville. He also chaired the Industry Advisory Board for the Computer Engineering and Computer Science Deptartment at the University of Louisville’s Speed School of Engineering for several years.

David C. Schie, CEO of Linear Dimensions, is a pioneer in solving motion and noise artifact rejection, battery lifetime, and form factor issues, which are major hurdles to the creation of practical wearable solutions. David’s vision to advance the wearables revolution is bringing together analog & mixed semiconductor power, analog neural algorithmic, industrial design, and systems engineering capabilities. David has been recognized for overcoming many motion and noise problems of contact and non-contact physiological measurements, optimizing the extraction of ECG and other signals during exercise. System results include lowest-power portable solutions for waveform extraction, which are being applied to noise cancelling audio as well as EMG/EEG (muscle/brain)-based control.

Before joining Linear Dimensions, David was Sr. Vice President of Power Management and High Reliability Semiconductors at Semtech; Vice President & General Manager of Analog/Power/RF Communications at Micrel; and Executive Director at Maxim Integrated Products. David graduated from the University of Toronto, PEng, Electrical.

Sumaiya Sharmeen, JD is a Student-at-Law at Deeth Williams Wall LLP, a boutique firm that offers a diverse range of services relating to emerging technologies. She has worked in various areas of intellectual property law, including patent litigation and prosecution, regulatory matters, and providing patentability and infringement opinions. As a Fellow at the IP Osgoode Innovation Clinic, she has helped clients develop IP strategies to protect and commercialize their inventions. She recently graduated from Osgoode Hall Law School and holds a B.Sc. in Biotechnology and M.Sc. in Medical Biophysics from the University of Toronto.

Julielynn Wong

Julielynn Wong, MD, MPH, is a Harvard-educated, award-winning physician, innovator, and communicator. Dr. Wong founded the Center for Innovative Technologies and Public Health, whose mission is to educate leaders on applying technologies to address the greatest challenges in healthcare. She worked at the San Francisco-based Skoll Global Threats Fund to build "Flu Near You," the world’s largest crowd-sourced flu tracking and vaccine locator platform, and trained in space medicine at NASA Johnson Space Center and founded 3D4MD, which creates 3D printable medical supplies to deliver healthcare in the most challenging places to those who need it the most.

Dr. Wong serves as a faculty lecturer at Singularity University and co-founded its Digital Health and Wellness Program. She specializes in medical communications, having reported for ABC World News, Forbes and the Huffington Post, and made numerous television appearances, including an Emmy-nominated series on Discovery Channel. Her mission is to empower medical experts to harness multi-media platforms to positively impact billions of people.

Nicholas Wong, JD is a partner at Deeth Williams Wall LLP, a boutique firm that offers a diverse range of services relating to emerging technologies. His areas of practice include intellectual property litigation, proceedings under the Patented Medicines (Notice of Compliance) Regulations, and the preparation and prosecution of patents and industrial designs. He also advises clients in commercial transactions relating to intellectual property and information technology, including drafting and negotiating asset purchase agreements, technology venture financing, and other matters relating to corporate governance.

sponsor logos